Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
Lapatinib is an intracellular tyrosine kinase inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptors, approved for the treatment of metastatic breast carcinoma pre-treated with anti-HER2 antibodies. We report the case of a 60-year-old woman diagnosed with metastatic breast neoplasm, HER2-positive, pr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-06-01
|
| Series: | AboutOpen |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/158 |